These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28475969)

  • 1. Investigation of substrate recognition for cytochrome P450 1A2 mediated by water molecules using docking and molecular dynamics simulations.
    Watanabe Y; Fukuyoshi S; Kato K; Hiratsuka M; Yamaotsu N; Hirono S; Gouda H; Oda A
    J Mol Graph Model; 2017 Jun; 74():326-336. PubMed ID: 28475969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2.
    Cho US; Park EY; Dong MS; Park BS; Kim K; Kim KH
    Biochim Biophys Acta; 2003 May; 1648(1-2):195-202. PubMed ID: 12758162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of three-dimensional structures and structural flexibilities of wild-type and mutant cytochrome P450 1A2 using molecular dynamics simulations.
    Watanabe Y; Fukuyoshi S; Hiratsuka M; Yamaotsu N; Hirono S; Takahashi O; Oda A
    J Mol Graph Model; 2016 Jul; 68():48-56. PubMed ID: 27371932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
    Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
    Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular basis for the inhibition of human cytochrome P450 1A2 by oroxylin and wogonin.
    Shao YX; Zhao P; Li Z; Liu M; Liu P; Huang M; Luo HB
    Eur Biophys J; 2012 Mar; 41(3):297-306. PubMed ID: 22228220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
    Kubo M; Yamamoto K; Itoh T
    Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes.
    Raunio H; Juvonen RO; Poso A; Lahtela-Kakkonen M; Rahnasto-Rilla M
    Drug Metab Lett; 2016; 10(1):56-64. PubMed ID: 26648056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
    Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
    J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible docking-based molecular dynamics/steered molecular dynamics calculations of protein-protein contacts in a complex of cytochrome P450 1A2 with cytochrome b5.
    Jeřábek P; Florián J; Stiborová M; Martínek V
    Biochemistry; 2014 Oct; 53(42):6695-705. PubMed ID: 25313797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of ligand binding to human cytochrome P-450 1A2: conformational activation and stabilization by alpha-naphthoflavone.
    Cho US; Ahn HJ; Park EY; Dong MS; Kim KH
    Biochim Biophys Acta; 2001 Apr; 1546(2):412-21. PubMed ID: 11295446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
    Jerabek P; Martinek V; Stiborova M
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.
    He L; He F; Bi H; Li J; Zeng S; Luo HB; Huang M
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6008-12. PubMed ID: 20832301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity.
    McEneny-King A; Osman W; Edginton AN; Rao PPN
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2443-2449. PubMed ID: 28400237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.
    Sridhar J; Goyal N; Liu J; Foroozesh M
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28698457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phe-125 and Phe-226 of pig cytochrome P450 1A2 stabilize the binding of aflatoxin B
    Zhu S; Wu J; Liu S; Jiang T; Deng Y
    Biochem Pharmacol; 2019 Aug; 166():292-299. PubMed ID: 31173723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of 7-methoxyresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding.
    Kim D; Guengerich FP
    Arch Biochem Biophys; 2004 Dec; 432(1):102-8. PubMed ID: 15519301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants.
    Tu Y; Deshmukh R; Sivaneri M; Szklarz GD
    Drug Metab Dispos; 2008 Nov; 36(11):2371-80. PubMed ID: 18703643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the activity of surface displayed cytochrome P450 enzymes by optimizing the outer membrane linker.
    Quehl P; Schüürmann J; Hollender J; Jose J
    Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):104-116. PubMed ID: 27814979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmentally persistent free radical-containing particulate matter competitively inhibits metabolism by cytochrome P450 1A2.
    Reed JR; dela Cruz AL; Lomnicki SM; Backes WL
    Toxicol Appl Pharmacol; 2015 Dec; 289(2):223-30. PubMed ID: 26423927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modeling of a three-dimensional structure of cytochrome P-450 1A2 and search for its new ligands].
    Belkina NV; Skvortsov VS; Ivanov AS; Archakov AI
    Vopr Med Khim; 1998; 44(5):464-73. PubMed ID: 9916262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.